Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi
- PMID: 18053636
- DOI: 10.1016/j.eururo.2007.11.006
Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi
Abstract
A 75-yr-old previously healthy woman presented with gross hematuria, European Cooperative Oncology Group 0, and an 11-cm renal mass with right atrial thrombus. The patient refused the sternotomy. She was offered two cycles of sunitinib maleate (Sutent) induction therapy to down-stage the thrombus and to reduce the extent of the surgery.
Comment in
-
Re: Pierre I. Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al. Neoadjuvant Sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008;53:845-8.Eur Urol. 2008 Oct;54(4):950-1; author reply 951-3. doi: 10.1016/j.eururo.2008.04.103. Epub 2008 May 9. Eur Urol. 2008. PMID: 18486309 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
